Mitocin (Mitomycin)

Mitomycin, the active ingredient in Mitocin, creates covalent cross‑links between DNA strands within bladder tumor cells, blocking DNA synthesis and triggering cell death, which helps prevent tumor recurrence.

The prescribed dose of Mitocin is determined by the treating physician based on the patient’s clinical condition, tumor characteristics and institutional protocol. Dosing details are not disclosed publicly.

Mitocin is contraindicated in pregnancy and breastfeeding because mitomycin can cross the placenta and be excreted in breast milk, potentially harming the fetus or infant. Women of child‑bearing potential should use effective contraception.

To order Mitocin, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Mitocin (mitomycin) is an alkylating agent that provides a direct DNA‑cross‑linking mechanism, whereas alternatives such as bacillus Calmette‑Guérin (BCG) stimulate an immune response. Choice depends on tumor type, prior therapy, patient tolerance and physician preference.

Mitocin should be stored below 25 °C in its original container, protected from light and moisture. Do not freeze. Use aseptic technique when preparing the intravesical solution and discard any unused portion after the recommended time.

Mitocin is administered as a sterile solution instilled directly into the bladder through a catheter, typically after transurethral resection of the tumor. The dwell time and number of installations are defined by the treating physician.

Serious risks include myelosuppression leading to severe neutropenia or thrombocytopenia, acute renal impairment, pulmonary toxicity, and systemic absorption causing gastrointestinal toxicity. Prompt medical evaluation is required if these occur.

Mitocin should not be used in patients with active urinary tract infection, severe renal impairment, known hypersensitivity to mitomycin, or those receiving concurrent high‑dose nephrotoxic or myelotoxic therapies without specialist supervision.